Morphological Basis of Pulmonary Edema in Mice with Cytokine-Induced Vascular Leak Syndrome
- 1 January 1991
- journal article
- Published by Taylor & Francis in Experimental Lung Research
- Vol. 17 (6) , 1095-1108
- https://doi.org/10.3109/01902149109064337
Abstract
Patients injected systemically with recombinant human interleukin-2 (rhIL-2) for treatment of solid tumor develop a vascular leak syndrome (VLS), characterized mainly by pulmonary edema whose pathogenesis is unknown. We have examined the structure of pulmonary vessels in mice with severe VLS induced by systemic injections of rhIL-2 and recombinant human interferon-alpha-A/D (rhIFN-alpha), which has a synergistic effect with IL-2. The pulmonary edema was associated with lesions of venous and capillary endothelia, alveolar basement membrane, and type I epithelial cells. These changes were more severe and diffuse than those seen in mice systemically injected with rhIL-2 alone, and in beige mice (deficient in NK cells and certain enzymes of polymorphonuclear leukocytes) injected with rhIL-2 and rhIFN-alpha. The endothelial lesions were comparable to those seen when leukocytes activated by cytokines react with activated endothelial cells in vitro, or at the site of injection of cytokines in vivo. The observations are in agreement with the interpretation that the severe lesions occurring in mice systemically injected with rhIL-2 with rhIFN-alpha result from the interaction of leukocytes with the endothelium. The results confirm the validity of previous studies performed in vitro or in animals injected intradermally with cytokines and extend their significance.Keywords
This publication has 32 references indexed in Scilit:
- Effects of cytokines on vascular endothelium: Their role in vascular and immune injuryKidney International, 1989
- Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers.Journal of Clinical Investigation, 1989
- Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.The Journal of Experimental Medicine, 1989
- Increased Vascular Permeability in Organs Mediated by the Systemic Administration of Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 in MiceJNCI Journal of the National Cancer Institute, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Interaction of recombinant interferons with recombinant interleukin-2: Differential effects on natural killer cell activity and interleukin-2-activated killer cellsInternational Journal of Cancer, 1986
- Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coliScience, 1984
- Acute Interstitial Nephritis with the Nephrotic Syndrome Following Recombinant Leukocyte A Interferon Therapy for Mycosis FungoidesNew England Journal of Medicine, 1984
- Defective T-cell response in beige mutant miceNature, 1982
- Lymphocyte and blast cell glomerulonephritis in renal allografts of rats injected with phytohaemagglutininCellular Immunology, 1974